LianBio (NASDAQ:LIAN) Shares Up 5.8%

LianBio (NASDAQ:LIAN) shares rose 5.8% during mid-day trading on Wednesday . The company traded as high as $0.36 and last traded at $0.36. Approximately 3,680 shares changed hands during mid-day trading, a decline of 100% from the average daily volume of 1,037,083 shares. The stock had previously closed at $0.34.

LianBio Stock Up 5.8 %

The company’s 50-day moving average is $0.32 and its 200-day moving average is $0.61. The stock has a market capitalization of $38.87 million, a price-to-earnings ratio of -0.44 and a beta of 0.23.

Institutional Trading of LianBio

A hedge fund recently raised its stake in LianBio stock. Affinity Asset Advisors LLC boosted its stake in LianBio (NASDAQ:LIAN) by 462.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,779,694 shares of the company’s stock after buying an additional 3,107,337 shares during the period. LianBio makes up approximately 3.1% of Affinity Asset Advisors LLC’s portfolio, making the stock its 9th biggest position. Affinity Asset Advisors LLC owned about 3.50% of LianBio worth $16,895,000 as of its most recent filing with the Securities and Exchange Commission. 74.85% of the stock is currently owned by institutional investors and hedge funds.

LianBio Company Profile

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.